A variable level of response of HER2 positive BC to NACT (with the same therapeutic agents) has been reported, with pCR rates ranging from 23 to 70% in various studies.23,34,35 Although the NACT pCR rate of the IHC 2+ BCs with evidence of HER2 amplification does not appear to differ from that of HER2 negative cases (IHC 0/1+), which varies between 10 and 35%,23,34,36 the magnitude of benefit from the addition of anti-HER2 targeted therapy is more important. The gene discussed is ERBB2; the disease is breast cancer.